Business & Regulation

Here’s a roundup of ten of the most eye-catching deals so far in 2025.

A look at how biosimilars can increase patient access to essential medicines, as well as improve performance in healthcare systems.

The Trump administration’s move to pause federal funding while projects are vetted causes concern and lawsuits

What can we expect the US life sciences sector to look like over the course of the next four years as Donald Trump takes up his presidency?

Watch our video interview covering Claus Zieler’s career and passion for improving investment in Europe.

Why mRNA will be a key disrupter in the coming years; experts from CureVac and Omega Therapeutics give their views.

With US courts consistently ruling in favor of the PrEP drug manufacture, the CDC and DHHS have had no choice but to be humble.

What lies ahead for the future of pharma? Dennis van Rooji gives his view.

Trump withdraws the US from the WHO and pharma stakeholders call for changes to price negotiation program

AI helps make preclinical decisions faster, but stakeholders remain cautious. We asked an expert from Elsevier for their views on the challenges.